A cleardose effect with a statistically significant response in theHAL5 % group of 95 % ( 18/19 patients ) compared to 57 % ( 12/21 patients ) in the placebo group ( P < .001 ) was observed at 3months in women with CIN 2 , including an encouraging 83 % ( 5/6 patients ) clearance of HPV 16/18 compared to 33 % ( 2/6 patients ) in the placebo group at 6 months .